5Forero A, Lobuglio AF. History of antibody therapy for nonHodgkin's lymphoma [J]. Semin Oncol, 2003,30(6 Suppl 17):1-5.
6Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project [J]. J Clin Oncol, 1998,16(8):2780-2795.
7Marcus R. Current treatment options in aggressive lymphoma[J]. Leuk Lymphoma, 2003,44 Suppl 4:S15-27.
8Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma [J]. N Engl J Med, 1993,328(14): 1002-1006.
9Webb MS, Saltman DL, Connors JM, et al. A literature review of single agent treatment of multiply relapsed aggressive nonHodgkin's lymphoma [J]. Leuk Lymphoma, 2002,43(5):975-982.
10Gianni AM, Berinstein NL, Evans PA, et al. Stem-cell transplantation in non-Hodgkin's lymphoma: improving outcome[J]. Anticancer Drugs, 2002,13 Suppl 2:S35-42.
6Yun J,Kim SJ,Kim JA,et al.Clinical features and treatment outcomes of non-Hodgkin′s lymphomas involving rare extranodal sites:a single-center experience[J].Acta Haematol,2010,123(1):48.
7Zwick C,Gleissner B,Pfreundschuh M.Aspects of chemotherapy schedules in young and elderly patients with aggressive lymphoma[J].Clin Lymphoma Myeloma,2007,8(Suppl 2):S43.
8Wilson WH,Gutierrez M,O′Connor P,et al.The role of rituximab and chemotherapy in aggressive B-cell lymphoma:a preliminary report of dose-adjusted EPOCH-R[J].Semin Oncol,2002,29(1 Suppl 2):41.
9Kewalramani T,Zelenetz AD,Nimer SD,et al.Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma[J].Blood,2004,103(10):3684.
